Amarin is unlike most other companies. No longer a biotech "startup" (ie. not in clinical/research stage), commercialized, but they backslid after losing the patents. Loss of patent in largest market, industry disagreement on their ONLY product (ie. mineral oil debacle, etc.), a series of mis-steps, management/board attacked by activist shareholder, slower-than-expected rollout in Europe (plus resistance from certain countries), loss of NASDAQ listing, and lack of "sense of urgency" by management and board, coupled with no forward guidance.
Basically, a horribly run company with a good product (and a string of bad luck).
They are essentially having to claw their way back from the brink. Unfortunately for us, they have to earn back their market cap. They will. But it's just going to take more time.
Market Data 
Markets 
AI
